In addition, glucose-lowering medications show inconsistent associations with lung cancer risk, that is, an apparent decreased risk with metformin [33] and increased risk with insulin and insulin secretagogues, with potential for confounding by indication [34]. The gene discussed is INS; the disease is lung cancer.